Clinical Trial Update: Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated thoracic radiotherapy plus durvalumab in elderly and/or frail patients with non-small cell lung cancer stage III who are unfit for che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: NSCLC, Stage III | Phase 2 | Status: COMPLETED